## Edgar Filing: Hamel Lawrence G - Form 4

Hamel Lawre Form 4	ence G										
September 27	7, 2017										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Weshington D.C. 20549								OMB AI OMB Number:	PPROVAL 3235-0287		
Check this if no long subject to Section 10	er <b>STATEM</b> 6.	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
Form 4 or Form 5 obligations may continue.response0Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400										0.5	
(Print or Type R	lesponses)										
Hamel Lawrence G Symbol ACELR				IARI	Ticker or T MACEU			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
C/O ACELRX (Month/D 09/25/20 PHARMACEUTICALS, INC., 351				Earliest Transaction ay/Year)				Director 10% Owner X Officer (give title Other (specify below) Chief Development Officer			
GALVESTON DRIVE (Street) 4. If Amendmen Filed(Month/Day/				nent, Date Original Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
REDWOOD	CITY, CA 9406	3						Form filed by M Person	fore than One Re	eporting	
(City)	(State) (	Zip)	Table I - N	on-D	erivative S	ecurit	ties Acq	quired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ate, if Tran Code	e	4. Securit on(A) or Dis (D) (Instr. 3, 4	sposed 4 and 5 (A)	l of	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common			Code	e V	Amount	or (D)	Price	(Instr. 3 and 4)		See	
Stock	09/25/2017		S		13,827	D	<u>(2)</u>	68,504 <u>(3)</u>	I <u>(1)</u>	footnote $(1)$	
Reminder: Repo	ort on a separate line :	for each class	of securities b	enefi	Person informa	s who ation	o respo contai	indirectly. ond to the collec ned in this form a	are not	EC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

## Edgar Filing: Hamel Lawrence G - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	Director 10% Owner Officer		Other			
Hamel Lawrence G C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY, CA 94063			Chief Development Officer				
Signatures							

/s/ Martha Adler, as attorney-in-fact

09/27/2017 Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 52,125 of the Shares are held in the Hamel Revocable Living Trust
- (2) The Shares were sold in a range from \$3.50-\$4.50
- (3) Non-reportable acquisition of 1,977 shares of Common Stock through the Company's Employee Stock Purchase Plan

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.